Sariyo Therapeutics

Sariyo Therapeutics is a biotechnology company focused on utilizing and developing improved formulations of naturally derived compounds for the treatment of severe, rare, and life-threatening diseases, aiming to gain approval from the European Medicines Evaluation Agency and the U.S. Food and Drug Administration (“FDA”). Sariyo is advancing the clinical development of its lead candidate drug, Cepharanthine, a repurposed and reformulated naturally derived compound, for the potential treatment of cancer, neurological disorders, inflammatory conditions, and infectious diseases.